2 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Untitled document
    2
    1. karim2001khoury 19 Feb 2026
      A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment

      [Paper-level Aggregated] PMCID: PMC8453302

      Evidence Type(s): Oncogenic, Prognostic

      Justification: Oncogenic: The G292R variant in HER2 is associated with a complete response to treatment, indicating its role in driving cancer progression and treatment response in metastatic cervical adenocarcinoma. Prognostic: The mention of a progression-free survival of 25 months in a patient with the G292R variant suggests that this variant may have implications for predicting treatment outcomes in cervical cancer.

      Gene→Variant (gene-first): ERBB2(2064):G292R

      Genes: ERBB2(2064)

      Variants: G292R

      CIViC paper-level aggregated PMC8453302
    2. karim2001khoury 19 Feb 2026
      Cervical cancer patients who develop distant metastasis are rarely curable with very limited treatment options. Chemotherapy is often administered but with limited efficacy. Immunotherapy and anti-angiogenesis therapy ar

      [Paragraph-level] PMCID: PMC8453302 Section: ABSTRACT PassageIndex: 2

      Evidence Type(s): Predictive, Oncogenic

      Justification: Predictive: The variant G292R in HER2 is associated with a complete response to pyrotinib treatment in a patient with metastatic cervical adenocarcinoma, indicating its correlation with therapy response. Oncogenic: The passage discusses the HER2 G292R variant in the context of a metastatic cervical adenocarcinoma, suggesting that it contributes to tumor development or progression.

      Gene→Variant (gene-first): 2064:G292R

      Genes: 2064

      Variants: G292R

      CIViC paragraph-level PMC8453302 Predictive Oncogenic
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC8453302/pdf/ott-14-4833.pdf